abstract: UNASSIGNED: Data on the agreement between aggregometry and platelet activation by flow cytometry regarding the measurement of on-treatment platelet reactivity to @entity6 (AA) and @entity3 ( @entity3 ) are scarce. We therefore sought to compare three @entity5 tests with flow cytometry for the assessment of the response to antiplatelet therapy. Platelet aggregation in response to AA and @entity3 was determined by light transmission aggregometry (LTA), the VerifyNow assays, and @entity2 ( @entity2 ) in 316 @entity0 receiving @entity1 and @entity4 therapy after angioplasty with stent implantation. AA- and @entity3 -induced @entity9 expression and activated glycoprotein (GP) IIb/IIIa were determined by flow cytometry. LTA, the VerifyNow @entity8 assay and @entity2 in response to @entity3 correlated significantly (all p<0.001), and the best correlation was observed between LTA and the VerifyNow @entity8 assay (r = 0.63). @entity3 -induced platelet reactivity by all aggregation tests correlated significantly with @entity3 -induced @entity9 expression and activated @entity7 /IIIa (all p<0.001). The best correlation was seen between the VerifyNow @entity8 assay and activated @entity7 /IIIa (r = 0.68). The platelet surface expressions of @entity9 and activated @entity7 /IIIa in response to @entity3 were significantly higher in @entity0 with high on-treatment residual platelet reactivity (HRPR) to @entity3 by all test systems (all p<0.001). A rather poor correlation was observed between AA-induced platelet reactivity by LTA and the VerifyNow @entity1 assay (r = 0.15, p = 0.007), while both methods did not correlate with @entity2 . AA-induced platelet reactivity by all aggregation tests correlated significantly, but rather poorly with AA-induced @entity9 expression (all p<0.05), while only AA-induced platelet reactivity by LTA correlated significantly with AA-induced activated @entity7 /IIIa (r = 0.21, p<0.001). The platelet surface expression of @entity9 in response to AA was significantly higher in @entity0 with HRPR by LTA AA and @entity2 (both p<0.02). In contrast, @entity9 expression in response to AA was similar in @entity0 without and with HRPR by the VerifyNow @entity1 assay (p = 0.5), and platelet surface activated @entity7 /IIIa in response to AA did not differ significantly between @entity0 without and with HRPR to AA by all test systems (all p>0.1). In conclusion, @entity3 -induced platelet reactivity by aggregometry translates partly into flow cytometry. In contrast, AA-induced platelet reactivity correlates poorly between different @entity5 tests, and between aggregometry and flow cytometry. Overall, both approaches capture different aspects of platelet function and are therefore not interchangeable in the assessment of agonists  -induced platelet reactivity. Clinical outcome data are needed to determine which test systems and settings are associated with different in vivo consequences.

title: Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists  -Induced Platelet Reactivity in XXXX on Dual Antiplatelet Therapy.

answer: @entity0


abstract: In most @entity1 disturbed production of cytokines and of their receptors can be noted. The main immune system cells engaged in @entity1 regression with the involvement of cytokines include helper lymphocytes ( @entity5 ), cytotoxic lymphocytes (Tc) and dendritic cells. It has been noted that cytokines are also produced by the cells of a @entity1 . The present study aimed at immunocytochemical localisation of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, @entity2 ) in @entity7 in @entity0 (n = 10). The studies were performed on surgical material following formalin fixation and embedding in paraffin. The control material involved @entity0 reactive lymph nodes (n = 5). @entity6 , @entity3 , IL-12 were detected in 4/10 examined cases. Expression of @entity4 was highly pronounced, as in the control, and was detected in 6/9 examined @entity0 . No @entity2 could be demonstrated in @entity1 even if lymph node expression of the cytokine was demonstrated in the control. The studies pointed to a decreased production of antitumour cytokines in @entity7 in @entity0 , which might correspond to the progression of the @entity1 .

title: Tissue expression of cytokines ( XXXX , @entity6 , @entity3 , IL-12, @entity2 ) in @entity7 in @entity0 .

answer: @entity4


abstract: In most @entity1 disturbed production of cytokines and of their receptors can be noted. The main immune system cells engaged in @entity1 regression with the involvement of cytokines include helper lymphocytes ( @entity5 ), cytotoxic lymphocytes (Tc) and dendritic cells. It has been noted that cytokines are also produced by the cells of a @entity1 . The present study aimed at immunocytochemical localisation of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, @entity2 ) in @entity7 in @entity0 (n = 10). The studies were performed on surgical material following formalin fixation and embedding in paraffin. The control material involved @entity0 reactive lymph nodes (n = 5). @entity6 , @entity3 , IL-12 were detected in 4/10 examined cases. Expression of @entity4 was highly pronounced, as in the control, and was detected in 6/9 examined @entity0 . No @entity2 could be demonstrated in @entity1 even if lymph node expression of the cytokine was demonstrated in the control. The studies pointed to a decreased production of antitumour cytokines in @entity7 in @entity0 , which might correspond to the progression of the @entity1 .

title: Tissue expression of cytokines ( @entity4 , XXXX , @entity3 , IL-12, @entity2 ) in @entity7 in @entity0 .

answer: @entity6


abstract: In most @entity1 disturbed production of cytokines and of their receptors can be noted. The main immune system cells engaged in @entity1 regression with the involvement of cytokines include helper lymphocytes ( @entity5 ), cytotoxic lymphocytes (Tc) and dendritic cells. It has been noted that cytokines are also produced by the cells of a @entity1 . The present study aimed at immunocytochemical localisation of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, @entity2 ) in @entity7 in @entity0 (n = 10). The studies were performed on surgical material following formalin fixation and embedding in paraffin. The control material involved @entity0 reactive lymph nodes (n = 5). @entity6 , @entity3 , IL-12 were detected in 4/10 examined cases. Expression of @entity4 was highly pronounced, as in the control, and was detected in 6/9 examined @entity0 . No @entity2 could be demonstrated in @entity1 even if lymph node expression of the cytokine was demonstrated in the control. The studies pointed to a decreased production of antitumour cytokines in @entity7 in @entity0 , which might correspond to the progression of the @entity1 .

title: Tissue expression of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, @entity2 ) in XXXX in @entity0 .

answer: @entity7


abstract: In most @entity1 disturbed production of cytokines and of their receptors can be noted. The main immune system cells engaged in @entity1 regression with the involvement of cytokines include helper lymphocytes ( @entity5 ), cytotoxic lymphocytes (Tc) and dendritic cells. It has been noted that cytokines are also produced by the cells of a @entity1 . The present study aimed at immunocytochemical localisation of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, @entity2 ) in @entity7 in @entity0 (n = 10). The studies were performed on surgical material following formalin fixation and embedding in paraffin. The control material involved @entity0 reactive lymph nodes (n = 5). @entity6 , @entity3 , IL-12 were detected in 4/10 examined cases. Expression of @entity4 was highly pronounced, as in the control, and was detected in 6/9 examined @entity0 . No @entity2 could be demonstrated in @entity1 even if lymph node expression of the cytokine was demonstrated in the control. The studies pointed to a decreased production of antitumour cytokines in @entity7 in @entity0 , which might correspond to the progression of the @entity1 .

title: Tissue expression of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, XXXX ) in @entity7 in @entity0 .

answer: @entity2


abstract: In most @entity1 disturbed production of cytokines and of their receptors can be noted. The main immune system cells engaged in @entity1 regression with the involvement of cytokines include helper lymphocytes ( @entity5 ), cytotoxic lymphocytes (Tc) and dendritic cells. It has been noted that cytokines are also produced by the cells of a @entity1 . The present study aimed at immunocytochemical localisation of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, @entity2 ) in @entity7 in @entity0 (n = 10). The studies were performed on surgical material following formalin fixation and embedding in paraffin. The control material involved @entity0 reactive lymph nodes (n = 5). @entity6 , @entity3 , IL-12 were detected in 4/10 examined cases. Expression of @entity4 was highly pronounced, as in the control, and was detected in 6/9 examined @entity0 . No @entity2 could be demonstrated in @entity1 even if lymph node expression of the cytokine was demonstrated in the control. The studies pointed to a decreased production of antitumour cytokines in @entity7 in @entity0 , which might correspond to the progression of the @entity1 .

title: Tissue expression of cytokines ( @entity4 , @entity6 , XXXX , IL-12, @entity2 ) in @entity7 in @entity0 .

answer: @entity3


abstract: In most @entity1 disturbed production of cytokines and of their receptors can be noted. The main immune system cells engaged in @entity1 regression with the involvement of cytokines include helper lymphocytes ( @entity5 ), cytotoxic lymphocytes (Tc) and dendritic cells. It has been noted that cytokines are also produced by the cells of a @entity1 . The present study aimed at immunocytochemical localisation of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, @entity2 ) in @entity7 in @entity0 (n = 10). The studies were performed on surgical material following formalin fixation and embedding in paraffin. The control material involved @entity0 reactive lymph nodes (n = 5). @entity6 , @entity3 , IL-12 were detected in 4/10 examined cases. Expression of @entity4 was highly pronounced, as in the control, and was detected in 6/9 examined @entity0 . No @entity2 could be demonstrated in @entity1 even if lymph node expression of the cytokine was demonstrated in the control. The studies pointed to a decreased production of antitumour cytokines in @entity7 in @entity0 , which might correspond to the progression of the @entity1 .

title: Tissue expression of cytokines ( @entity4 , @entity6 , @entity3 , IL-12, @entity2 ) in @entity7 in XXXX .

answer: @entity0


abstract: BACKGROUND: @entity2 ( @entity2 ) is one of the most commonly diagnosed @entity1 worldwide. Two standard approaches for treatment of resectable @entity2 include adjuvant @entity6 -based chemoradiotherapy [per Intergroup 0116 (INT-0116) trial and perioperative @entity4 , @entity3 , @entity6 (ECF) chemotherapy per Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial]. Controversy remains regarding the most appropriate treatment strategy to decrease recurrence rates and improve survival following surgery. The purpose of this study was to analyze how patterns of care for @entity0 with @entity2 treated at Emory University Hospital changed following publication of the MAGIC trial in 2006. METHODS: We analyzed a prospectively maintained database of 150 @entity0 who underwent resection for @entity2 between December 2000 and June 2013. @entity0 were divided into two cohorts, Early [2000-2006] and late [2007-2013]. The primary objective was to compare the number of @entity0 assigned to adjuvant chemoradiotherapy (aCRT) vs. perioperative chemotherapy (PC) throughout the study period and secondarily assess for recurrence patterns and survival outcomes for @entity0 assigned to those two strategies. RESULTS: Between 2000 and 2013, 124 @entity0 received adjuvant therapy for @entity2 . Fifty-four @entity0 were treated with PC and 70 @entity0 with aCRT. The early cohort included 56 @entity0 , and the late cohort included 94 @entity0 . There was no statistical difference in the number of @entity0 receiving aCRT between the Early and Late cohorts [n=23 (50%) vs. 35 (38%) respectively, P=0.21]. PC increased from 2 @entity0 (3.6%) in the Early cohort to 32 @entity0 (34%) in the Late cohort (P<0.001). Four-year @entity5 ( @entity5 ) was 32.6% for the Early cohort and 68.8% for the Late cohort (P=0.010). Overall recurrence rate was 25.3% with no significant difference in rates of recurrence seen between the Early and Late cohorts. CONCLUSIONS: PC has become more prevalent in @entity0 treated at Emory following publication of the MAGIC trial in 2006. @entity5 , but not recurrence rates, has also improved since publication. Although improved survival is suggestive of improved care, the question of optimal treatment regimen remains open. Further prospective comparisons of PC and aCRT are needed to identify @entity0 and disease parameters that may guide therapy selection.

title: Radiotherapy patterns of care in XXXX : a single institution experience.

answer: @entity2


abstract: The epididymis is an @entity1 -dependent organ. The hormones regulate the morphology and secretory activity of the epididymal epithelial cells. The cells in vitro resume their function as in vivo and also reveal features of steroidogenic cells. It can be expected that, as with Leydig cells, the morphology and function of the cells can be regulated by LH/ @entity4 . The aim of the study was to assess the morphology of epididymal epithelial cells in vitro after stimulation with @entity4 . The experiment was performed on cells isolated from sexually mature @entity0 . The epididymal epithelial cells were cultured in a medium with the addition of @entity2 ( @entity3 ). Moreover, the cells were cultured in the medium with @entity3 and without @entity3 but enriched with @entity4 . The epididymal epithelial cells cultured with @entity3 formed a monolayer and accumulated glycogen, a PAS-positive substance and lipid droplets. The cells cultured without @entity3 were stellate in shape and low in glycogen and PASpositive substance but they contained lipid droplets. The morphology of epididymal epithelial cells cultured without @entity3 but after stimulation with @entity4 was similar to the morphology of the cells cultured with @entity3 . This was the first sign that the morphology of the cells can be influenced by @entity4 .

title: Effect of XXXX on the morphology of @entity0 epididymal epithelial cells in vitro.

answer: @entity4


abstract: The epididymis is an @entity1 -dependent organ. The hormones regulate the morphology and secretory activity of the epididymal epithelial cells. The cells in vitro resume their function as in vivo and also reveal features of steroidogenic cells. It can be expected that, as with Leydig cells, the morphology and function of the cells can be regulated by LH/ @entity4 . The aim of the study was to assess the morphology of epididymal epithelial cells in vitro after stimulation with @entity4 . The experiment was performed on cells isolated from sexually mature @entity0 . The epididymal epithelial cells were cultured in a medium with the addition of @entity2 ( @entity3 ). Moreover, the cells were cultured in the medium with @entity3 and without @entity3 but enriched with @entity4 . The epididymal epithelial cells cultured with @entity3 formed a monolayer and accumulated glycogen, a PAS-positive substance and lipid droplets. The cells cultured without @entity3 were stellate in shape and low in glycogen and PASpositive substance but they contained lipid droplets. The morphology of epididymal epithelial cells cultured without @entity3 but after stimulation with @entity4 was similar to the morphology of the cells cultured with @entity3 . This was the first sign that the morphology of the cells can be influenced by @entity4 .

title: Effect of @entity4 on the morphology of XXXX epididymal epithelial cells in vitro.

answer: @entity0


abstract: OBJECTIVE: The aim of this study is to analyze the quantitative DTI parameters of the CST in @entity0 suffering from @entity2 affecting the CST using generally available navigation software. METHODS: A retrospective study was conducted on 22 subjects with diagnosis of primary @entity3 and preoperative @entity4 . Exclusion criteria were: involvement of motor cortex, lesion involving both hemispheres, previous surgical treatment. All @entity0 were studied using magnetic resonance imaging (MRI) with diffusion tensor imaging (DTI) sequences. Volume, fractional anisotropy (FA) and @entity5 ( @entity5 ) of the entire CSTs were estimated. Moreover, distance from midline, diameters, FA and @entity5 were calculated on axial images at the point of minimal distance between @entity1 and CST. Statistical analysis was performed. RESULTS: There was a statistically significant difference of CST volume between affected and non-affected hemispheres (p<0.01). Mean overall/local FA, overall/local @entity5 and sagittal diameter of CST were also significantly different between the two sides (p<0.05). Correlation tests resulted positive between the shift of CST and overall/local @entity5 . Moreover there is significance between CST volume of @entity1 hemisphere and preoperative duration of @entity4 (p<0.05). CONCLUSION: The present study has demonstrated for the first time a significant difference of DTI based quantitative parameters of the CST between a @entity1 affected and a non-affected hemisphere in @entity0 with a corresponding motor deficit. This preliminary data suggests a correlation between DTI based integrity of CST and its function.

title: Assessment of quantitative corticospinal tract diffusion changes in @entity0 affected by XXXX using common available navigation software.

answer: @entity2


abstract: OBJECTIVE: The aim of this study is to analyze the quantitative DTI parameters of the CST in @entity0 suffering from @entity2 affecting the CST using generally available navigation software. METHODS: A retrospective study was conducted on 22 subjects with diagnosis of primary @entity3 and preoperative @entity4 . Exclusion criteria were: involvement of motor cortex, lesion involving both hemispheres, previous surgical treatment. All @entity0 were studied using magnetic resonance imaging (MRI) with diffusion tensor imaging (DTI) sequences. Volume, fractional anisotropy (FA) and @entity5 ( @entity5 ) of the entire CSTs were estimated. Moreover, distance from midline, diameters, FA and @entity5 were calculated on axial images at the point of minimal distance between @entity1 and CST. Statistical analysis was performed. RESULTS: There was a statistically significant difference of CST volume between affected and non-affected hemispheres (p<0.01). Mean overall/local FA, overall/local @entity5 and sagittal diameter of CST were also significantly different between the two sides (p<0.05). Correlation tests resulted positive between the shift of CST and overall/local @entity5 . Moreover there is significance between CST volume of @entity1 hemisphere and preoperative duration of @entity4 (p<0.05). CONCLUSION: The present study has demonstrated for the first time a significant difference of DTI based quantitative parameters of the CST between a @entity1 affected and a non-affected hemisphere in @entity0 with a corresponding motor deficit. This preliminary data suggests a correlation between DTI based integrity of CST and its function.

title: Assessment of quantitative corticospinal tract diffusion changes in XXXX affected by @entity2 using common available navigation software.

answer: @entity0


abstract: CONTEXT: Bioelectronic sensors, which combine microchip and biological components, are an emerging technology in clinical diagnostic testing. An electronic detection platform using DNA biochip technology (eSensor) is under development for molecular diagnostic applications. Owing to the novelty of these devices, demonstrations of their successful use in practical diagnostic applications are limited. OBJECTIVE: To assess the performance of the eSensor bioelectronic method in the validation of 6 @entity3 -transformed blood lymphocyte cell lines with clinically important mutations for use as sources of genetic material for positive controls in clinical molecular genetic testing. Two cell lines carry mutations in the @entity1 gene ( @entity0 ), and 4 carry mutations in the @entity4 gene ( @entity2 ). DESIGN: Samples from each cell line were sent for genotype determination to 6 different molecular genetic testing facilities, including the laboratory developing the DNA biochips. In addition to the bioelectronic method, at least 3 different molecular diagnostic methods were used in the analysis of each cell line. Detailed data were collected from the DNA biochip output, and the genetic results were compared with those obtained using the more established methods. RESULTS: We report the successful use of 2 applications of the bioelectronic platform, one for detection of @entity1 mutations and the other for detection of @entity4 mutations. In all cases, the results obtained with the DNA biochip were in concordance with those reported for the other methods. Electronic signal output from the DNA biochips clearly differentiated between mutated and wild-type alleles. This is the first report of the use of the @entity0 detection platform. CONCLUSIONS: Bioelectronic sensors for the detection of disease-causing mutations performed well when used in a "real-life" situation, in this case, a validation study of positive control blood lymphocyte cell lines with mutations of public health importance. This study illustrates the practical potential of emerging bioelectronic DNA detection technologies for use in current molecular diagnostic applications.

title: Bioelectronic sensor technology for detection of XXXX and @entity2 mutations.

answer: @entity0


abstract: CONTEXT: Bioelectronic sensors, which combine microchip and biological components, are an emerging technology in clinical diagnostic testing. An electronic detection platform using DNA biochip technology (eSensor) is under development for molecular diagnostic applications. Owing to the novelty of these devices, demonstrations of their successful use in practical diagnostic applications are limited. OBJECTIVE: To assess the performance of the eSensor bioelectronic method in the validation of 6 @entity3 -transformed blood lymphocyte cell lines with clinically important mutations for use as sources of genetic material for positive controls in clinical molecular genetic testing. Two cell lines carry mutations in the @entity1 gene ( @entity0 ), and 4 carry mutations in the @entity4 gene ( @entity2 ). DESIGN: Samples from each cell line were sent for genotype determination to 6 different molecular genetic testing facilities, including the laboratory developing the DNA biochips. In addition to the bioelectronic method, at least 3 different molecular diagnostic methods were used in the analysis of each cell line. Detailed data were collected from the DNA biochip output, and the genetic results were compared with those obtained using the more established methods. RESULTS: We report the successful use of 2 applications of the bioelectronic platform, one for detection of @entity1 mutations and the other for detection of @entity4 mutations. In all cases, the results obtained with the DNA biochip were in concordance with those reported for the other methods. Electronic signal output from the DNA biochips clearly differentiated between mutated and wild-type alleles. This is the first report of the use of the @entity0 detection platform. CONCLUSIONS: Bioelectronic sensors for the detection of disease-causing mutations performed well when used in a "real-life" situation, in this case, a validation study of positive control blood lymphocyte cell lines with mutations of public health importance. This study illustrates the practical potential of emerging bioelectronic DNA detection technologies for use in current molecular diagnostic applications.

title: Bioelectronic sensor technology for detection of @entity0 and XXXX mutations.

answer: @entity2


abstract: OBJECTIVE: Matrix metalloproteinases (MMPs) play an important role in pathogenesis of @entity6 and @entity5 . We hypothesized that @entity7 might be a susceptibility gene for @entity3 ( @entity3 ) in @entity1 . The aim of this study was to evaluate the association between C(-1306)T functional polymorphism in the @entity7 gene and risk of @entity3 in type 2 @entity1 @entity0 . METHODS: We examined 1090 @entity0 with T2DM and 612 controls. All subjects were genotyped for the C(-1306)T polymorphism by polymerase chain reaction (PCR) and restriction analysis. RESULTS: A significant @entity4 allele frequency was observed in @entity0 with @entity3 versus those with no @entity3 (OR 0.44, 95% CI 0.36-0.52, p<0.0001). In contrast, OR for CC genotype was 2.19 (1.79-2.68, p<0.0001), conferring 2-fold greater odds for @entity3 . When the distribution of C(-1306)T was compared in subgroups with different clinical phenotypes of @entity3 , @entity0 with @entity2 had the lowest frequency of T allele (6% vs. 11%), compared to entire @entity3 + group (p<0.05). CONCLUSIONS: T2DM @entity0 carrying the T allele of @entity7 C(-1306)T polymorphism have a significantly reduced risk of @entity3 . The C(-1306)T polymorphism is associated with susceptibility to @entity2 in T2DM @entity0 .

title: XXXX ( @entity7 ) gene polymorphism and cardiovascular comorbidity in type 2 @entity1 @entity0 .

answer: @entity7


abstract: OBJECTIVE: Matrix metalloproteinases (MMPs) play an important role in pathogenesis of @entity6 and @entity5 . We hypothesized that @entity7 might be a susceptibility gene for @entity3 ( @entity3 ) in @entity1 . The aim of this study was to evaluate the association between C(-1306)T functional polymorphism in the @entity7 gene and risk of @entity3 in type 2 @entity1 @entity0 . METHODS: We examined 1090 @entity0 with T2DM and 612 controls. All subjects were genotyped for the C(-1306)T polymorphism by polymerase chain reaction (PCR) and restriction analysis. RESULTS: A significant @entity4 allele frequency was observed in @entity0 with @entity3 versus those with no @entity3 (OR 0.44, 95% CI 0.36-0.52, p<0.0001). In contrast, OR for CC genotype was 2.19 (1.79-2.68, p<0.0001), conferring 2-fold greater odds for @entity3 . When the distribution of C(-1306)T was compared in subgroups with different clinical phenotypes of @entity3 , @entity0 with @entity2 had the lowest frequency of T allele (6% vs. 11%), compared to entire @entity3 + group (p<0.05). CONCLUSIONS: T2DM @entity0 carrying the T allele of @entity7 C(-1306)T polymorphism have a significantly reduced risk of @entity3 . The C(-1306)T polymorphism is associated with susceptibility to @entity2 in T2DM @entity0 .

title: @entity7 ( XXXX ) gene polymorphism and cardiovascular comorbidity in type 2 @entity1 @entity0 .

answer: @entity7


abstract: OBJECTIVE: Matrix metalloproteinases (MMPs) play an important role in pathogenesis of @entity6 and @entity5 . We hypothesized that @entity7 might be a susceptibility gene for @entity3 ( @entity3 ) in @entity1 . The aim of this study was to evaluate the association between C(-1306)T functional polymorphism in the @entity7 gene and risk of @entity3 in type 2 @entity1 @entity0 . METHODS: We examined 1090 @entity0 with T2DM and 612 controls. All subjects were genotyped for the C(-1306)T polymorphism by polymerase chain reaction (PCR) and restriction analysis. RESULTS: A significant @entity4 allele frequency was observed in @entity0 with @entity3 versus those with no @entity3 (OR 0.44, 95% CI 0.36-0.52, p<0.0001). In contrast, OR for CC genotype was 2.19 (1.79-2.68, p<0.0001), conferring 2-fold greater odds for @entity3 . When the distribution of C(-1306)T was compared in subgroups with different clinical phenotypes of @entity3 , @entity0 with @entity2 had the lowest frequency of T allele (6% vs. 11%), compared to entire @entity3 + group (p<0.05). CONCLUSIONS: T2DM @entity0 carrying the T allele of @entity7 C(-1306)T polymorphism have a significantly reduced risk of @entity3 . The C(-1306)T polymorphism is associated with susceptibility to @entity2 in T2DM @entity0 .

title: @entity7 ( @entity7 ) gene polymorphism and cardiovascular comorbidity in type 2 XXXX @entity0 .

answer: @entity1


abstract: OBJECTIVE: Matrix metalloproteinases (MMPs) play an important role in pathogenesis of @entity6 and @entity5 . We hypothesized that @entity7 might be a susceptibility gene for @entity3 ( @entity3 ) in @entity1 . The aim of this study was to evaluate the association between C(-1306)T functional polymorphism in the @entity7 gene and risk of @entity3 in type 2 @entity1 @entity0 . METHODS: We examined 1090 @entity0 with T2DM and 612 controls. All subjects were genotyped for the C(-1306)T polymorphism by polymerase chain reaction (PCR) and restriction analysis. RESULTS: A significant @entity4 allele frequency was observed in @entity0 with @entity3 versus those with no @entity3 (OR 0.44, 95% CI 0.36-0.52, p<0.0001). In contrast, OR for CC genotype was 2.19 (1.79-2.68, p<0.0001), conferring 2-fold greater odds for @entity3 . When the distribution of C(-1306)T was compared in subgroups with different clinical phenotypes of @entity3 , @entity0 with @entity2 had the lowest frequency of T allele (6% vs. 11%), compared to entire @entity3 + group (p<0.05). CONCLUSIONS: T2DM @entity0 carrying the T allele of @entity7 C(-1306)T polymorphism have a significantly reduced risk of @entity3 . The C(-1306)T polymorphism is associated with susceptibility to @entity2 in T2DM @entity0 .

title: @entity7 ( @entity7 ) gene polymorphism and cardiovascular comorbidity in type 2 @entity1 XXXX .

answer: @entity0


abstract: The @entity5 represents a specific clustering of cardiovascular risk factors. One of several recently proposed definitions encompasses 3 or more of the following 5 abnormalities: waist circumference > 102 cm in @entity0 or > 88 cm in women, serum @entity7 level > or = 150 mg/dL, high-density lipoprotein @entity4 level < 40 mg/dL in @entity0 or < 50 mg/dL in @entity0 , blood pressure (BP) > or = 130/> or = 85 mm Hg and serum @entity8 > or = 110 mg/dL. The diagnosis of @entity5 allows early recognition of an increased risk of @entity3 . African Americans have the highest coronary heart disease mortality of any ethnic group in the United States. African-American @entity0 and Hispanic @entity0 and @entity0 have the highest prevalence of the @entity5 . This phenomenon is attributable mainly to the disproportionate occurrence of elevated BP, @entity2 , and @entity1 in African Americans, and the high prevalence of @entity2 and @entity1 in Hispanics. Management of the @entity5 consists primarily of modification or reversal of the root causes and direct therapy of the risk factors. The first strategy involves @entity6 and increased physical activity, both of which can improve all components of the syndrome. The second strategy often involves drug treatment of the individual risk factors to further improve BP, lipids, and @entity8 thereby decreasing the risk of @entity3 . This comprehensive review is provided as part of the educational activities of the African-American Lipid and Cardiovascular Council (AALCC).

title: The XXXX in African Americans: a review.

answer: @entity5


abstract: OBJECTIVE: Our purpose was to test the hypothesis that the intra-amniotic injection of a retroviral vector producer cell line into pregnant @entity2 will result in retrovirus-mediated transduction and stable gene transfer to the ovine fetus. STUDY DESIGN: Thirteen pregnant ewes at various gestational ages underwent amniocentesis and injection of cells producing the retrovirus vector LIRESgeo, which is derived from Maloney @entity0 @entity4 virus and encodes @entity1 LacZ (beta-galactosidase) as a marker gene. Pregnant ewes and fetuses were killed, and amniotic fluid, placenta, and fetal tissues were collected and assayed for transgene expression 7 to 77 days after intraamniotic injection. In addition, serum was collected and analyzed for evidence of specific immune responses against the producer cells, and amniotic fluid was collected and analyzed for deleterious effects on producer cell viability, vector production, and vector transduction. RESULTS: Only 1 of 10 fetuses exposed to the retroviral producer cells demonstrated beta-galactosidase activity that correlated with positive immunohistochemistry for LacZ in lung, @entity3 , pancreas, and small intestine. However, the presence of the LacZ gene could not be confirmed by polymerase chain reaction. Thus, we could not confirm transduction after any of the injections. The retroviral producer cells survived well in amniotic fluid and continued to produce high levels of retroviral vector after intra-amniotic injection, although amniotic fluid inhibited the transducing activity of the vector in a manner dependent on gestational age. CONCLUSIONS: Intra-amniotic retroviral gene transfer with the use of these amphotropic producer cells does not result in reproducible gene transfer in the ovine fetus although amniotic fluid sustains producer cell viability and vector production. Possible reasons for the inefficient transduction are discussed.

title: Inefficient transduction of XXXX in utero after intra-amniotic injection of retroviral producer cells.

answer: @entity2


abstract: AIM: To analyse the clinical characteristics of @entity0 on the Bradford Low Vision Register with regards to the type (partially sighted or blind), sex, race, causes and age at registration. METHODS: All the data were obtained from the Morley Street Resource Centre, which keeps records of all registrations in the Bradford Metropolitan District. Information including postcode, date of birth, age, gender, ethnic group, degree, date of registration, cause of registration and age at registration were entered into a database. RESULTS: Of all registrations, 64% were blind and 36% were partially sighted. Asians were younger at registration and there were a significantly lower number of females compared to Caucasians. When data were analysed for the different age groups, in the older group of over 65 years, Asians showed significantly more @entity1 (26.1%) compared to Asians (7.8%), while Caucasians demonstrated significantly more @entity4 (C: 29.3%; A: 17.4%). In the younger age group (<30 years), the leading causes for Asians were @entity6 and @entity3 while for Caucasians it was @entity2 and @entity5 . The proportion of Asians registered was significantly lower than expected from the projected population estimates in Bradford. CONCLUSIONS: The study indicates significant differences in the clinical profiles of the two racial groups. The data do not follow the predictions from published population estimates, with Asians, especially females, being under-represented in the register.

title: The clinical characteristics of Asian and Caucasian XXXX on Bradford's Low Vision Register.

answer: @entity0


abstract: OBJECTIVE: We aimed to assess use of and interest in mobile health (mHealth) technology and in- @entity0 services for @entity1 self-care in vulnerable populations. METHODS: We delivered a self-administered cross-sectional survey. @entity0 were recruited at two primary care practices ( @entity2 ) with P1 located in a medically underserved area and P2 in an affluent suburb. Two-sample t-tests and chi-square tests were used with p   <   0.05 significant. In addition, a secondary analysis was performed to analyse differences in use and interest in mHealth by age. RESULTS: Of 75 eligible @entity0 , 60 completed the survey (80% response rate). P1 @entity0 had significantly higher interest in three of five categories of in- @entity0 @entity1 support services, one of four categories of health-related text messages (TM), and three of eight categories of mHealth applications (p   <   0.05). Smartphone users reported higher interest in TM (p   =   0.004) and mHealth applications for @entity1 self-care (p   =   0.004). Younger @entity0 were more likely to have a smartphone (p   <   0.006), use the Internet (p   <   0.0012), use smartphone applications (p   <   0.0004), and to be interested in using applications to manage their @entity1 (p   <   0.004). DISCUSSION: This study shows substantial @entity0 interest in TM and mHealth applications for @entity1 self-care and suggests that @entity0 in underserved areas may have particularly high interest in using mHealth solutions in primary care. Younger @entity0 and smartphone users were more likely to be interested in using applications to manage their @entity1 . As more @entity0 use smartphones, interest in using mHealth to support @entity0 self-care and strengthen primary care infrastructure will continue to grow.

title: Use of and interest in mobile health for XXXX self-care in vulnerable populations.

answer: @entity1


abstract: Antigen treatment of neonatal epidermis results in antigen-specific immune suppression. Compared with adult counterparts, neonatal Langerhans' cells (LC) demonstrate an impaired ability to transport antigen to the @entity1 ( @entity1 ). As it is possible that neonatal LC have a reduced ability to endocytose antigen, we evaluated the acquisition of endocytic function, the expression of uptake receptors and the internalization of soluble and small particulate antigens in neonatal, juvenile and adult @entity0 . Although LC from 4-day-old @entity0 were weakly positive for the @entity5 -type receptor, @entity6 , they were capable of internalizing @entity3 ( @entity4 )-dextran, but to a lesser extent than LC from 6-week-old @entity0 . However, when ratio data were calculated to account for variations in fluorescence intensity at 4 degrees, it was demonstrated that neonatal LC continued to internalize antigen over a longer period of time than adult @entity0 and, as the ratios were much higher, that neonatal cells were also relatively more efficient in antigen uptake. When receptors for mannan and @entity5 were competitively blocked, LC from neonatal @entity0 , but not adult @entity0 , could still efficiently internalize @entity4 -dextran. Consequently, the uptake of @entity4 -dextran, in part, occurred via alternative receptors or a receptor-independent fluid-phase pathway. A feasible pathway is macropinocytosis, as LC from 4-day-old @entity0 demonstrated a reduction in @entity4 -dextran internalization by the macropinocytosis inhibitor, @entity2 . Evidence of a functional macropinocytosis pathway in neonatal LC was further supported by internalization of the soluble tracer Lucifer Yellow (LY). We conclude that neonatal LC preferentially utilize a @entity2 -sensitive, fluid-phase pathway, rather than receptor-mediated endocytosis, to internalize antigen. As neonatal LC are capable of sampling their environment without inducing immunity, this may serve to avoid inappropriate immune responses during the neonatal period.

title: DEC-205lo Langerinlo neonatal Langerhans' cells preferentially utilize a XXXX -sensitive, fluid-phase pathway to internalize exogenous antigen.

answer: @entity2


abstract: The selective accumulation of different leucocyte populations during @entity2 is regulated by adhesion molecules and chemokines expressed by vascular endothelium. This study examined how chemokine production and the expression of adhesion molecules and chemokine receptors vary between endothelia from different vascular beds. @entity0 saphenous vein endothelium was compared with lung and dermal microvascular endothelia and with umbilical vein endothelium and a bone-marrow endothelial cell line. All endothelia produced @entity10 and @entity9 constitutively, whereas @entity6 and @entity12 were only secreted after @entity1 @entity3 factor ( @entity4 or @entity7 stimulation. In combination with @entity4 , @entity7 suppressed @entity9 but enhanced @entity12 and @entity6 , whereas transforming growth factor (TGF)-beta reduced secretion of all chemokines. Basal chemokine secretion was higher from umbilical vein than other endothelial cells. Chemokine receptors, @entity13 , @entity5 and @entity18 , were present on all endothelia but highest on saphenous vein. @entity16 , @entity11 , @entity15 , @entity14 , @entity8 and @entity17 were also detected at variable levels on different endothelia. The variation between endothelia in chemokine secretion was much greater than the variations in adhesion molecules, both on resting cells and following cytokine stimulation. These results indicate that it is the tissue-specific variations in endothelial chemokine secretion rather than variations in adhesion molecules that can explain the different patterns of @entity2 and leucocyte traffic seen in non-lymphoid tissues.

title: Chemokines, chemokine receptors and adhesion molecules on different XXXX endothelia: discriminating the tissue-specific functions that affect leucocyte migration.

answer: @entity0


abstract: UNASSIGNED: Florfenicol (FFC) residues in foods are regulated as the sum of @entity3 and its metabolites measured as @entity5 ( @entity0 ). An isotope dilution LC-MS/MS method utilizing @entity4 ( @entity2 ) SPE cleanup is established for the accurate determination of @entity0 in fish muscles (i.e., salmon and tilapia) after acid catalyzed hydrolysis. Comparisons of the @entity2 SPE cleanup procedure with other cleanup procedures such as mixed-mode cationic (MCX) SPE and solid supported liquid-liquid extraction were performed. Quantification of @entity0 in fish muscles was accomplished by using matrix-matched calibration with @entity0 -D3 as the internal standard. The method was validated with @entity0 fortified fish muscles at three different levels (50, 100, and 200  g/kg). Conversion of FFC to @entity0 by acid catalyzed hydrolysis was evaluated and found to be >= 88%. The recoveries of @entity0 in fish muscles at the three fortification levels ranged from 89 to 106%, and @entity1 were  <=9% in all cases. The LOD values in salmon and tilapia muscles were 0.13 and 1.64  g/kg, respectively. The LOQ values in salmon and tilapia muscles were 0.29 and 4.13  g/kg, respectively. This method is suitable for the application in routine control of FFC in fishes according to its residue definition.

title: XXXX Solid Phase Extraction Cleanup and Isotope Dilution Liquid Chromatography-Tandem Mass Spectrometry for the Determination of @entity5 in Fish Muscles.

answer: @entity4


abstract: UNASSIGNED: Florfenicol (FFC) residues in foods are regulated as the sum of @entity3 and its metabolites measured as @entity5 ( @entity0 ). An isotope dilution LC-MS/MS method utilizing @entity4 ( @entity2 ) SPE cleanup is established for the accurate determination of @entity0 in fish muscles (i.e., salmon and tilapia) after acid catalyzed hydrolysis. Comparisons of the @entity2 SPE cleanup procedure with other cleanup procedures such as mixed-mode cationic (MCX) SPE and solid supported liquid-liquid extraction were performed. Quantification of @entity0 in fish muscles was accomplished by using matrix-matched calibration with @entity0 -D3 as the internal standard. The method was validated with @entity0 fortified fish muscles at three different levels (50, 100, and 200  g/kg). Conversion of FFC to @entity0 by acid catalyzed hydrolysis was evaluated and found to be >= 88%. The recoveries of @entity0 in fish muscles at the three fortification levels ranged from 89 to 106%, and @entity1 were  <=9% in all cases. The LOD values in salmon and tilapia muscles were 0.13 and 1.64  g/kg, respectively. The LOQ values in salmon and tilapia muscles were 0.29 and 4.13  g/kg, respectively. This method is suitable for the application in routine control of FFC in fishes according to its residue definition.

title: @entity4 Solid Phase Extraction Cleanup and Isotope Dilution Liquid Chromatography-Tandem Mass Spectrometry for the Determination of XXXX in Fish Muscles.

answer: @entity5


abstract: BACKGROUND: @entity6 's pharmacological, hemodynamic, and electrophysiological properties are well understood. However, in modern @entity2 ( @entity2 ) treatment, its effect has yet to be fully investigated. OBJECTIVE: The aim of the present study was to determine the effects of @entity6 on outcomes in @entity0 with mild @entity2 implanted with an @entity3 ( @entity3 ) or cardiac resynchronization therapy with defibrillator (CRT-D) device. METHODS: We investigated the effect of @entity6 treatment on the end points of @entity2 / @entity1 , @entity2 alone, @entity1 alone, and @entity4 or @entity5 (VT/VF) in 1820 @entity0 with mild @entity2 (New York Heart Association class I and II), prolonged QRS duration (>= 130 ms), and reduced left ventricular ejection fraction ( <=30%) enrolled in the Multicenter Automatic Defibrillator Implantation Trial - Cardiac Resynchronization Therapy trial. Multivariate Cox proportional hazards regression models were used to determine the effect of time-dependent @entity6 usage on the end points. RESULTS: @entity6 therapy was not associated with an increased or decreased risk of @entity2 / @entity1 (hazard ratio [HR] 1.07; 95% confidence interval [CI] 0.86-1.33; P = .0.56), @entity2 alone (HR 1.1.04; 95% CI 0.82-1.32; P = .76), or @entity1 alone (HR 0.93; 95% CI 0.67-1.32; P = .71). However, @entity6 was associated with a significant 41% increased risk of VT/VF (HR 1.41; 95% CI 1.14-1.75; P = .002), which was driven by a significantly increased risk of VT/VF with heart rate >= 200 beats/min (HR 1.65; 95% CI 1.27-2.15; P  <= .001), whereas no increased risk of VT/VF with heart rate <200 beats/min was evident (HR 1.20; 95% CI 0.92-1.57; P = .19). No significant differences in @entity6 's effect on any of the end points were found between @entity0 with @entity3 and @entity0 with CRT-D (interaction P > .5). CONCLUSION: The use of @entity6 in @entity0 with mild @entity2 implanted with an @entity3 or CRT-D device was not associated with reductions in @entity2 / @entity1 events. However, @entity6 therapy was associated with an increased risk of high-rate VT/VF (>= 200 beats/min).

title: XXXX therapy and associated clinical outcomes in the MADIT-CRT trial.

answer: @entity6


abstract: UNASSIGNED: It is generally accepted that optimal particle sizes are key for efficient nanocatalysis. Much less attention is paid to the role of morphology and atomic arrangement during catalytic reactions. Here, we unravel the structural, stoichiometric, and morphological evolution of gas-phase produced and partially oxidized @entity0 nanoparticles in a broad size range. Particles with diameters between 1.4 and 22 nm generated in cluster sources are size selected and deposited on amorphous @entity1 ( @entity4 ) and ultrananocrystalline @entity2 (UNCD) films. A combination of different techniques is employed to monitor particle properties at the stages of production, exposure to ambient conditions, and catalytic reaction, in this case, the oxidative dehydrogenation of @entity3 at elevated temperatures. A pronounced size dependence is found, naturally classifying the particles into three size regimes. While small and intermediate clusters essentially retain their compact morphology, large particles transform into hollow spheres due to the nanoscale Kirkendall effect. Depending on the substrate, an isotropic ( @entity4 ) or anisotropic (UNCD) Kirkendall effect is observed. The latter results in dramatic lateral size changes. Our results shed light on the interplay between chemical reactions and the catalyst's structure and provide an approach to tailor the @entity5 phase composition required for specific catalytic schemes.

title: Pronounced Size Dependence in Structure and Morphology of Gas-Phase Produced, Partially Oxidized XXXX Nanoparticles under Catalytic Reaction Conditions.

answer: @entity0


abstract: @entity4 containing medium- and long-chain @entity5 (TML) have medium- and long-chain @entity5 in the same molecule. The effects of dietary TML on serum lipid levels and body fat were studied in six young @entity0 belonging to a university rowing club. A double-blind crossover study was performed in which for 3 wk the subjects ingested a liquid diet containing 20 g/d of @entity3 oil or TML in addition to their regular diets. Throughout the study, they were asked to keep their usual lifestyle, including diet and physical activity. The body composition of the subjects was measured weekly. Blood samples were taken at 0, 2, and 3 wk of each treatment period. There was no significant difference in energy intake between the @entity3 oil diet period and the TML diet period. The rate of variation of serum @entity4 concentration was significantly lower after a consumption of the TML liquid diet for 3 wk compared with the @entity3 oil liquid diet. The rate of variation of body fat mass was also significantly lower after a consumption of the TML liquid diet for 3 wk compared with the @entity3 oil liquid diet. However, the serum @entity2 concentration did not change significantly during either dietary treatment. These results suggest that TML, compared with @entity3 oil, may have the potential to prevent @entity6 and @entity1 caused by consumption of a high-fat diet.

title: Effect of @entity4 containing medium- and long-chain XXXX on serum @entity4 levels and body fat in college athletes.

answer: @entity5


abstract: @entity4 containing medium- and long-chain @entity5 (TML) have medium- and long-chain @entity5 in the same molecule. The effects of dietary TML on serum lipid levels and body fat were studied in six young @entity0 belonging to a university rowing club. A double-blind crossover study was performed in which for 3 wk the subjects ingested a liquid diet containing 20 g/d of @entity3 oil or TML in addition to their regular diets. Throughout the study, they were asked to keep their usual lifestyle, including diet and physical activity. The body composition of the subjects was measured weekly. Blood samples were taken at 0, 2, and 3 wk of each treatment period. There was no significant difference in energy intake between the @entity3 oil diet period and the TML diet period. The rate of variation of serum @entity4 concentration was significantly lower after a consumption of the TML liquid diet for 3 wk compared with the @entity3 oil liquid diet. The rate of variation of body fat mass was also significantly lower after a consumption of the TML liquid diet for 3 wk compared with the @entity3 oil liquid diet. However, the serum @entity2 concentration did not change significantly during either dietary treatment. These results suggest that TML, compared with @entity3 oil, may have the potential to prevent @entity6 and @entity1 caused by consumption of a high-fat diet.

title: Effect of XXXX containing medium- and long-chain @entity5 on serum @entity4 levels and body fat in college athletes.

answer: @entity4


abstract: @entity4 containing medium- and long-chain @entity5 (TML) have medium- and long-chain @entity5 in the same molecule. The effects of dietary TML on serum lipid levels and body fat were studied in six young @entity0 belonging to a university rowing club. A double-blind crossover study was performed in which for 3 wk the subjects ingested a liquid diet containing 20 g/d of @entity3 oil or TML in addition to their regular diets. Throughout the study, they were asked to keep their usual lifestyle, including diet and physical activity. The body composition of the subjects was measured weekly. Blood samples were taken at 0, 2, and 3 wk of each treatment period. There was no significant difference in energy intake between the @entity3 oil diet period and the TML diet period. The rate of variation of serum @entity4 concentration was significantly lower after a consumption of the TML liquid diet for 3 wk compared with the @entity3 oil liquid diet. The rate of variation of body fat mass was also significantly lower after a consumption of the TML liquid diet for 3 wk compared with the @entity3 oil liquid diet. However, the serum @entity2 concentration did not change significantly during either dietary treatment. These results suggest that TML, compared with @entity3 oil, may have the potential to prevent @entity6 and @entity1 caused by consumption of a high-fat diet.

title: Effect of @entity4 containing medium- and long-chain @entity5 on serum XXXX levels and body fat in college athletes.

answer: @entity4


abstract: The green pit viper (Trimeresurus albolabris and Trimeresurus macrops) is a common venomous snake in Thailand. The green pit viper venom has major effects on the hematologic system. The venom is found to have a thrombin-like effect in vitro but cause a @entity2 in vivo. Unlike other pit viper snakes (such as Malayan pit viper and Russel's pit viper), the venomous effect on red blood cells is rarely mentioned. Clinical features of @entity3 vary from asymptomatic to fatal @entity1 . In this study, an attempt was made to discern hematologic parameters in green pit viper @entity3 and to characterize the changes in blood cells. The study included data from 40 @entity0 who were hospitalized at the King Chulalongkorn Memorial Hospital during 1995 to 1999 and 40 normal, healthy subjects as control. Concerning platelet determination, significantly decreased (p < 0.05) total platelet count and mean platelet volume ( @entity4 ) were demonstrated in envenomous blood. The changes in blood cells may be partly due to the effect of green pit viper toxin on the platelet morphology. However, the explanation of this phenomenon requires further investigation for the specific pathophysiology. The components of green pit viper venom that have these hematologic effects in @entity0 are interesting and should be further identified.

title: A trend of platelet indices in XXXX with green pit viper toxin.

answer: @entity0


abstract: Common genetic variation @entity6 in the @entity3 ( @entity3 ) gene has been considered to be implicated in the development of many @entity1 . Nevertheless, results from the related studies were inconsistent. To elucidate the association, we performed a meta-analysis for 8,112 cases and 10,037 controls from 32 published case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association by STATA 12.0 software. Overall, we revealed that the @entity3 -192R allele was associated with a reduced risk of the @entity1 . Moreover, in the stratified analysis by @entity1 types ( @entity0 , @entity2 , @entity5 etc.), the results showed that @entity3 -192R allele was associated with a decreased risk in @entity0 (R vs Q: OR=0.605, 95% CI=0.378-0.967, Pheterogeneity=0.000; RR vs QQ: OR=0.494, 95% CI=0.275-0.888, Pheterogeneity=0.002; RQ vs QQ: OR=0.465, 95% CI=0.259-0.835, Pheterogeneity=0.000; and RR+RQ vs QQ: OR=0.485, 95% CI=0.274-0.857, Pheterogeneity=0.000), and associated with @entity2 in homozygote (RR vs QQ: OR=0.475, 95% CI=0.251- 0.897, Pheterogeneity=0.001) and recessive models (RR vs RQ+QQ: OR=0.379, 95% CI=0.169-0.853, Pheterogeneity=0.000), while an increased risk was identified in @entity4 (R vs Q: OR=1.537, 95% CI=1.246-1.896, Pheterogeneity=0.944; RR vs QQ: OR=2.987, 95% CI=1.861-4.795, Pheterogeneity=0.350; RR+RQ vs QQ: OR=1.354, 95% CI=1.021-1.796, Pheterogeneity=0.824; and RR vs RQ+QQ: OR=2.934, 95% CI=1.869-4.605, Pheterogeneity=0.433), and an increased risk in @entity2 under heterozygote comparison (RQ vs QQ: OR=1.782, 95% CI=1.077-2.950, Pheterogeneity=0.000) and dominant models (RR+RQ vs QQ: OR=1.281, 95% CI=1.044-1.573, Pheterogeneity=0.056). When subgroup analysis that performed by the control source (hospital based or population based), a decreased risk of the @entity1 was revealed by homozygote (RR vs QQ: OR=0.601, 95% CI=0.366-0.987, Pheterogeneity=0.000) and dominant models (RR vs RQ+QQ: OR= 0.611, 95% CI=0.384-0.973, Pheterogeneity=0.000) in hospital based group. Stratifying by ethnicity, a significantly reduced risk of the @entity1 under allele contrast model (R vs Q: OR=0.788, 95% CI=0.626-0.993, Pheterogeneity=0.000) was uncovered in Caucasian. In summary, these findings suggested that @entity3 @entity6 polymorphism was associated with a reduced risk of the @entity1 , nevertheless, it might increase @entity1 susceptibility of prostate and @entity4 risk. Large well-designed epidemiological studies will be continued on this issue of interest.

title: XXXX ( @entity3 ) @entity6 Gene Polymorphism and Cancer Risk: A Meta-Analysis Based on 30 Publications.

answer: @entity3


abstract: Common genetic variation @entity6 in the @entity3 ( @entity3 ) gene has been considered to be implicated in the development of many @entity1 . Nevertheless, results from the related studies were inconsistent. To elucidate the association, we performed a meta-analysis for 8,112 cases and 10,037 controls from 32 published case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association by STATA 12.0 software. Overall, we revealed that the @entity3 -192R allele was associated with a reduced risk of the @entity1 . Moreover, in the stratified analysis by @entity1 types ( @entity0 , @entity2 , @entity5 etc.), the results showed that @entity3 -192R allele was associated with a decreased risk in @entity0 (R vs Q: OR=0.605, 95% CI=0.378-0.967, Pheterogeneity=0.000; RR vs QQ: OR=0.494, 95% CI=0.275-0.888, Pheterogeneity=0.002; RQ vs QQ: OR=0.465, 95% CI=0.259-0.835, Pheterogeneity=0.000; and RR+RQ vs QQ: OR=0.485, 95% CI=0.274-0.857, Pheterogeneity=0.000), and associated with @entity2 in homozygote (RR vs QQ: OR=0.475, 95% CI=0.251- 0.897, Pheterogeneity=0.001) and recessive models (RR vs RQ+QQ: OR=0.379, 95% CI=0.169-0.853, Pheterogeneity=0.000), while an increased risk was identified in @entity4 (R vs Q: OR=1.537, 95% CI=1.246-1.896, Pheterogeneity=0.944; RR vs QQ: OR=2.987, 95% CI=1.861-4.795, Pheterogeneity=0.350; RR+RQ vs QQ: OR=1.354, 95% CI=1.021-1.796, Pheterogeneity=0.824; and RR vs RQ+QQ: OR=2.934, 95% CI=1.869-4.605, Pheterogeneity=0.433), and an increased risk in @entity2 under heterozygote comparison (RQ vs QQ: OR=1.782, 95% CI=1.077-2.950, Pheterogeneity=0.000) and dominant models (RR+RQ vs QQ: OR=1.281, 95% CI=1.044-1.573, Pheterogeneity=0.056). When subgroup analysis that performed by the control source (hospital based or population based), a decreased risk of the @entity1 was revealed by homozygote (RR vs QQ: OR=0.601, 95% CI=0.366-0.987, Pheterogeneity=0.000) and dominant models (RR vs RQ+QQ: OR= 0.611, 95% CI=0.384-0.973, Pheterogeneity=0.000) in hospital based group. Stratifying by ethnicity, a significantly reduced risk of the @entity1 under allele contrast model (R vs Q: OR=0.788, 95% CI=0.626-0.993, Pheterogeneity=0.000) was uncovered in Caucasian. In summary, these findings suggested that @entity3 @entity6 polymorphism was associated with a reduced risk of the @entity1 , nevertheless, it might increase @entity1 susceptibility of prostate and @entity4 risk. Large well-designed epidemiological studies will be continued on this issue of interest.

title: @entity3 ( XXXX ) @entity6 Gene Polymorphism and Cancer Risk: A Meta-Analysis Based on 30 Publications.

answer: @entity3


abstract: Common genetic variation @entity6 in the @entity3 ( @entity3 ) gene has been considered to be implicated in the development of many @entity1 . Nevertheless, results from the related studies were inconsistent. To elucidate the association, we performed a meta-analysis for 8,112 cases and 10,037 controls from 32 published case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association by STATA 12.0 software. Overall, we revealed that the @entity3 -192R allele was associated with a reduced risk of the @entity1 . Moreover, in the stratified analysis by @entity1 types ( @entity0 , @entity2 , @entity5 etc.), the results showed that @entity3 -192R allele was associated with a decreased risk in @entity0 (R vs Q: OR=0.605, 95% CI=0.378-0.967, Pheterogeneity=0.000; RR vs QQ: OR=0.494, 95% CI=0.275-0.888, Pheterogeneity=0.002; RQ vs QQ: OR=0.465, 95% CI=0.259-0.835, Pheterogeneity=0.000; and RR+RQ vs QQ: OR=0.485, 95% CI=0.274-0.857, Pheterogeneity=0.000), and associated with @entity2 in homozygote (RR vs QQ: OR=0.475, 95% CI=0.251- 0.897, Pheterogeneity=0.001) and recessive models (RR vs RQ+QQ: OR=0.379, 95% CI=0.169-0.853, Pheterogeneity=0.000), while an increased risk was identified in @entity4 (R vs Q: OR=1.537, 95% CI=1.246-1.896, Pheterogeneity=0.944; RR vs QQ: OR=2.987, 95% CI=1.861-4.795, Pheterogeneity=0.350; RR+RQ vs QQ: OR=1.354, 95% CI=1.021-1.796, Pheterogeneity=0.824; and RR vs RQ+QQ: OR=2.934, 95% CI=1.869-4.605, Pheterogeneity=0.433), and an increased risk in @entity2 under heterozygote comparison (RQ vs QQ: OR=1.782, 95% CI=1.077-2.950, Pheterogeneity=0.000) and dominant models (RR+RQ vs QQ: OR=1.281, 95% CI=1.044-1.573, Pheterogeneity=0.056). When subgroup analysis that performed by the control source (hospital based or population based), a decreased risk of the @entity1 was revealed by homozygote (RR vs QQ: OR=0.601, 95% CI=0.366-0.987, Pheterogeneity=0.000) and dominant models (RR vs RQ+QQ: OR= 0.611, 95% CI=0.384-0.973, Pheterogeneity=0.000) in hospital based group. Stratifying by ethnicity, a significantly reduced risk of the @entity1 under allele contrast model (R vs Q: OR=0.788, 95% CI=0.626-0.993, Pheterogeneity=0.000) was uncovered in Caucasian. In summary, these findings suggested that @entity3 @entity6 polymorphism was associated with a reduced risk of the @entity1 , nevertheless, it might increase @entity1 susceptibility of prostate and @entity4 risk. Large well-designed epidemiological studies will be continued on this issue of interest.

title: @entity3 ( @entity3 ) XXXX Gene Polymorphism and Cancer Risk: A Meta-Analysis Based on 30 Publications.

answer: @entity6


abstract: Five experiments were conducted to evaluate the efficacy of @entity5 [ @entity4 ] to minimize the development of @entity3 ( @entity3 ) and improve phytate @entity1 retention in Ross cockerels during the starter period. In experiment 1, chicks were fed a @entity3 -inducing (0.67% @entity0 ) diet with or without exposure to ultraviolet light and no supplemental @entity2 . Dietary @entity4 was added at 0, 10, or 70 microg/kg for both light treatments. In experiment 2, @entity4 was added at 0, 10, 40, or 70 microg/kg to a @entity3 -inducing diet containing 27.5 microg/kg added @entity2 . Experiment 3 was similar to experiment 2 except a diet marginal (0.85%) in @entity0 was fed, and @entity2 was added at 55 microg/kg. In experiments 4 and 5, @entity4 was added at 0, 18, 36, 54, 72, or 90 microg/kg to a diet marginal in @entity0 . Dietary @entity4 decreased the incidence of @entity3 similarly at 40 and 70 microg/kg @entity4 and improved phytate @entity1 retention when the @entity3 -inducing diet was fed. The incidence of @entity3 was decreased when 70 microg/kg @entity4 was added to a diet marginal in @entity0 in experiment 3 only. Phytate @entity1 retention was generally not affected by dietary @entity4 when a diet containing marginal @entity0 , adequate @entity1 , and high @entity2 was fed. The effectiveness of @entity4 to reduce the incidence of @entity3 in young broilers was higher when the dietary @entity0 level was below 0.85%. The incidence of @entity3 in Ross cockerels was low (< 25%) when dietary @entity0 was greater than 0.85%.

title: Effectiveness of twenty-five-hydroxycholecalciferol in the prevention of XXXX in Ross cockerels depends on dietary @entity0 level.

answer: @entity3


abstract: Five experiments were conducted to evaluate the efficacy of @entity5 [ @entity4 ] to minimize the development of @entity3 ( @entity3 ) and improve phytate @entity1 retention in Ross cockerels during the starter period. In experiment 1, chicks were fed a @entity3 -inducing (0.67% @entity0 ) diet with or without exposure to ultraviolet light and no supplemental @entity2 . Dietary @entity4 was added at 0, 10, or 70 microg/kg for both light treatments. In experiment 2, @entity4 was added at 0, 10, 40, or 70 microg/kg to a @entity3 -inducing diet containing 27.5 microg/kg added @entity2 . Experiment 3 was similar to experiment 2 except a diet marginal (0.85%) in @entity0 was fed, and @entity2 was added at 55 microg/kg. In experiments 4 and 5, @entity4 was added at 0, 18, 36, 54, 72, or 90 microg/kg to a diet marginal in @entity0 . Dietary @entity4 decreased the incidence of @entity3 similarly at 40 and 70 microg/kg @entity4 and improved phytate @entity1 retention when the @entity3 -inducing diet was fed. The incidence of @entity3 was decreased when 70 microg/kg @entity4 was added to a diet marginal in @entity0 in experiment 3 only. Phytate @entity1 retention was generally not affected by dietary @entity4 when a diet containing marginal @entity0 , adequate @entity1 , and high @entity2 was fed. The effectiveness of @entity4 to reduce the incidence of @entity3 in young broilers was higher when the dietary @entity0 level was below 0.85%. The incidence of @entity3 in Ross cockerels was low (< 25%) when dietary @entity0 was greater than 0.85%.

title: Effectiveness of twenty-five-hydroxycholecalciferol in the prevention of @entity3 in Ross cockerels depends on dietary XXXX level.

answer: @entity0


abstract: OBJECTIVES: Our objectives were to examine the assumption that the natural history of congenital @entity1 in @entity0 presenting early and those presenting late is the same, and to determine whether there are factors that might predict the post-operative outcome of surgery among the presenting features of @entity0 with @entity1 . METHODS: The authors present a clinical series of 50 consecutive cases of @entity1 that had been treated surgically. All @entity0 underwent both pre- and post-operative urological assessment and pre-operative imaging with MRI. The case notes, urology assessments and MRI films were studied to provide data on the clinical presentation, follow-up history and urological outcome of the @entity0 , as well as on the anatomical features of their @entity1 . RESULTS: Analysis of the data revealed a predominance in @entity0 and a bimodal distribution of age at presentation with peaks at 0-2 and 7-8 years. Skin stigmata were more frequent in @entity0 below 6 years of age than in older @entity0 (P=0.035). The MRI scans demonstrated that the conus lay within the sacral canal more often in @entity0 than @entity0 (P=0.025). Severe @entity2 was significantly more frequent in those presenting at =3 years of age (P=0.017) and there were more normal outcomes in @entity0 operated upon before the age of 3 than in those operated upon at or after this age ( P<0.0001). Eight @entity0 who had been operated upon had severe urological problems at the time of their last assessment (median age of 8 years and 2 months). They were predominantly @entity0 with major pre-operative @entity3 . CONCLUSIONS: Formal pre-operative urological assessment proved to be the strongest determinant of final urological outcome. Other predictors of poor urological outcome were @entity1 size and sacral position for the @entity1 . This series demonstrates how early and late presenting @entity0 may represent different @entity0 groups, follow different natural histories and may therefore not be reliable for comparison purposes. Future studies of prophylactic untethering need to follow cohorts beyond the age of deterioration found in untreated cases (8 years) and must report the salient MRI features that we suggest are predictive of poor outcome.

title: XXXX : pitfalls in analysing the results of prophylactic surgery.

answer: @entity1


abstract: INTRODUCTION: @entity6 in @entity0 is a very rare entity. CASE REPORT: The authors present a case of @entity6 in a 23-month-old @entity0 . The @entity0 was admitted to our hospital with persistent @entity2 and frequent @entity3 . MR imaging demonstrated a large frontal well-circumscribed lesion with a heterogeneous @entity5 enhancement. Although macroscopically the @entity1 was totally extirpated, the @entity0 died of rapid @entity1 regrowth 2 months after surgery. The surgical specimens obtained from the @entity1 showed an admixture of two distinctive neoplastic tissues. One was a malignant mesenchymal feature. Its fibrosarcomatous nature was characterized by spindle-shaped cells with fine fibers that were deeply stained in @entity4 preparations for reticulin. The other was gliomatous tissue forming islands surrounded by the sarcomatous tissues. Its glioblastomatous nature was obvious, as it was characterized by endothelial proliferation and perinecrotic pseudopalisading. Both tissues were histologically malignant, as evidenced by mitotic figure, high cellularity, atypical features, and variability. DISCUSSION: The literature concerning @entity1 is reviewed, and pathological and clinical features of the @entity1 are briefly discussed.

title: XXXX : a case and a review of the literature.

answer: @entity6


abstract: PURPOSE: To test a novel strategy for overcoming intrinsic resistance to @entity5 ( @entity6 ) in @entity3 ( @entity3 ) due to @entity7 and nucleobase salvage (NS). METHODS: Four @entity3 cell lines, found to be highly resistant to @entity6 , were tested to determine the dominant mechanism of resistance. Sensitivity to @entity6 was tested in the presence of dialyzed serum or the transport inhibitor @entity11 (DP) to confirm the contribution of NS to @entity6 resistance. We then investigated whether increased NS activity could be exploited using cytotoxic @entity7 analogs. RESULTS: Like other cell types, @entity3 cells are capable of circumventing inhibition of de novo @entity2 synthesis by relying on NS. @entity6 , at concentrations as high as 1 m M did not inhibit cell growth in culture medium supplemented with undialyzed serum. In contrast, when NS was inhibited by DP or in medium depleted of @entity9 and nucleobases, sensitivity to @entity6 was seen at nanomolar concentrations. In medium with dialyzed serum, @entity4 and @entity10 provided dose-dependent protection from @entity6 @entity1 at concentrations similar to those seen in @entity0 plasma. No evidence of other significant mechanisms of resistance were found. All four cell lines were sensitive to 3-day exposures to @entity8 (IC50 0.22 to 2.88 micro M) and @entity12 (IC50 0.09 to 0.95 micro M). CONCLUSIONS: Salvage of de novo @entity2 synthesis inhibition by extracellular @entity4 and @entity10 , at physiologically relevant concentrations, contributes to resistance to @entity6 in @entity3 . However, this same process may impart a collateral sensitivity to @entity7 analogs. These findings support clinical trials for @entity0 with @entity3 using @entity7 analogs, either alone or in combination.

title: @entity3 cells, resistant to @entity5 due to XXXX and nucleobase salvage, are sensitive to @entity7 analogs.

answer: @entity7


abstract: PURPOSE: To test a novel strategy for overcoming intrinsic resistance to @entity5 ( @entity6 ) in @entity3 ( @entity3 ) due to @entity7 and nucleobase salvage (NS). METHODS: Four @entity3 cell lines, found to be highly resistant to @entity6 , were tested to determine the dominant mechanism of resistance. Sensitivity to @entity6 was tested in the presence of dialyzed serum or the transport inhibitor @entity11 (DP) to confirm the contribution of NS to @entity6 resistance. We then investigated whether increased NS activity could be exploited using cytotoxic @entity7 analogs. RESULTS: Like other cell types, @entity3 cells are capable of circumventing inhibition of de novo @entity2 synthesis by relying on NS. @entity6 , at concentrations as high as 1 m M did not inhibit cell growth in culture medium supplemented with undialyzed serum. In contrast, when NS was inhibited by DP or in medium depleted of @entity9 and nucleobases, sensitivity to @entity6 was seen at nanomolar concentrations. In medium with dialyzed serum, @entity4 and @entity10 provided dose-dependent protection from @entity6 @entity1 at concentrations similar to those seen in @entity0 plasma. No evidence of other significant mechanisms of resistance were found. All four cell lines were sensitive to 3-day exposures to @entity8 (IC50 0.22 to 2.88 micro M) and @entity12 (IC50 0.09 to 0.95 micro M). CONCLUSIONS: Salvage of de novo @entity2 synthesis inhibition by extracellular @entity4 and @entity10 , at physiologically relevant concentrations, contributes to resistance to @entity6 in @entity3 . However, this same process may impart a collateral sensitivity to @entity7 analogs. These findings support clinical trials for @entity0 with @entity3 using @entity7 analogs, either alone or in combination.

title: @entity3 cells, resistant to @entity5 due to @entity7 and nucleobase salvage, are sensitive to XXXX analogs.

answer: @entity7


abstract: PURPOSE: To test a novel strategy for overcoming intrinsic resistance to @entity5 ( @entity6 ) in @entity3 ( @entity3 ) due to @entity7 and nucleobase salvage (NS). METHODS: Four @entity3 cell lines, found to be highly resistant to @entity6 , were tested to determine the dominant mechanism of resistance. Sensitivity to @entity6 was tested in the presence of dialyzed serum or the transport inhibitor @entity11 (DP) to confirm the contribution of NS to @entity6 resistance. We then investigated whether increased NS activity could be exploited using cytotoxic @entity7 analogs. RESULTS: Like other cell types, @entity3 cells are capable of circumventing inhibition of de novo @entity2 synthesis by relying on NS. @entity6 , at concentrations as high as 1 m M did not inhibit cell growth in culture medium supplemented with undialyzed serum. In contrast, when NS was inhibited by DP or in medium depleted of @entity9 and nucleobases, sensitivity to @entity6 was seen at nanomolar concentrations. In medium with dialyzed serum, @entity4 and @entity10 provided dose-dependent protection from @entity6 @entity1 at concentrations similar to those seen in @entity0 plasma. No evidence of other significant mechanisms of resistance were found. All four cell lines were sensitive to 3-day exposures to @entity8 (IC50 0.22 to 2.88 micro M) and @entity12 (IC50 0.09 to 0.95 micro M). CONCLUSIONS: Salvage of de novo @entity2 synthesis inhibition by extracellular @entity4 and @entity10 , at physiologically relevant concentrations, contributes to resistance to @entity6 in @entity3 . However, this same process may impart a collateral sensitivity to @entity7 analogs. These findings support clinical trials for @entity0 with @entity3 using @entity7 analogs, either alone or in combination.

title: @entity3 cells, resistant to XXXX due to @entity7 and nucleobase salvage, are sensitive to @entity7 analogs.

answer: @entity5


abstract: PURPOSE: To test a novel strategy for overcoming intrinsic resistance to @entity5 ( @entity6 ) in @entity3 ( @entity3 ) due to @entity7 and nucleobase salvage (NS). METHODS: Four @entity3 cell lines, found to be highly resistant to @entity6 , were tested to determine the dominant mechanism of resistance. Sensitivity to @entity6 was tested in the presence of dialyzed serum or the transport inhibitor @entity11 (DP) to confirm the contribution of NS to @entity6 resistance. We then investigated whether increased NS activity could be exploited using cytotoxic @entity7 analogs. RESULTS: Like other cell types, @entity3 cells are capable of circumventing inhibition of de novo @entity2 synthesis by relying on NS. @entity6 , at concentrations as high as 1 m M did not inhibit cell growth in culture medium supplemented with undialyzed serum. In contrast, when NS was inhibited by DP or in medium depleted of @entity9 and nucleobases, sensitivity to @entity6 was seen at nanomolar concentrations. In medium with dialyzed serum, @entity4 and @entity10 provided dose-dependent protection from @entity6 @entity1 at concentrations similar to those seen in @entity0 plasma. No evidence of other significant mechanisms of resistance were found. All four cell lines were sensitive to 3-day exposures to @entity8 (IC50 0.22 to 2.88 micro M) and @entity12 (IC50 0.09 to 0.95 micro M). CONCLUSIONS: Salvage of de novo @entity2 synthesis inhibition by extracellular @entity4 and @entity10 , at physiologically relevant concentrations, contributes to resistance to @entity6 in @entity3 . However, this same process may impart a collateral sensitivity to @entity7 analogs. These findings support clinical trials for @entity0 with @entity3 using @entity7 analogs, either alone or in combination.

title: XXXX cells, resistant to @entity5 due to @entity7 and nucleobase salvage, are sensitive to @entity7 analogs.

answer: @entity3


abstract: PURPOSE: We report long-term disease control, survival, and @entity3 for @entity0 with locally advanced @entity4 prospectively treated with concurrent proton therapy and chemotherapy on a nonrandomized case-only observational study. METHODS: All @entity0 received passive-scatter proton therapy, planned with 4D-CT-based simulation; all received proton therapy concurrent with weekly chemotherapy. Endpoints were local and distant control, disease-free survival (DFS), and @entity5 ( @entity5 ). RESULTS: The 134 @entity0 (21 stage II, 113 stage III; median age 69years) had a median gross @entity1 volume (GTV) of 70cm(3) (range, 5-753cm(3)); 77 @entity0 (57%) received 74Gy(RBE), and 57 (42%) received 60-72Gy(RBE) (range, 60-74.1Gy(RBE)). At a median follow-up time of 4.7years, median @entity5 times were 40.4months (stage II) and 30.4months (stage III). Five-year DFS rates were 17.3% (stage II) and 18.0% (stage III). @entity5 , DFS, and local and distant control rates at 5years did not differ by disease stage. Age and GTV were related to @entity5 and DFS. @entity3 was tolerable, with 1 grade 4 @entity7 and 16 grade 3 events (2 @entity2 , 6 @entity7 , 8 @entity6 ). CONCLUSION: This report of outcomes after proton therapy for 134 @entity0 indicated that this regimen produced excellent @entity5 with tolerable @entity3 .

title: Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable XXXX .

answer: @entity4


abstract: BACKGROUND: Antibiotics and @entity7 have been employed in the management of fistulizing @entity1 , although evidence of their efficacy is rare. AIM: To evaluate, in a prospective, open-label study, the influence of antibiotics and @entity4 on the clinical outcome of perianal @entity3 in @entity0 with @entity1 . METHODS: Fifty-two @entity0 entered the study, starting with an 8-week regimen of @entity6 (500-1000 mg/day) and/or @entity5 (1000-1500 mg/day). Seventeen @entity0 had already received daily @entity4 (2-2.5 mg/kg) at enrollment, whereas in 14 @entity0 @entity4 was initiated after 8 weeks of antibiotic treatment. Outcome was evaluated by Fistula Drainage Assessment and the @entity2 Activity Index at weeks 8 and 20. RESULTS: Overall, 26 @entity0 (50%) responded to antibiotic treatment, with complete healing in 25% of @entity0 at week 8. The @entity2 Activity Index decreased significantly from 8.4 +/- 2.9 to 6.0 +/- 4.0 (P < 0.0001). At week 20, the outcome was assessed in 49 @entity0 (94%), 29 of whom (59%) had received @entity4 . Response was noted in 17 of the 49 @entity0 (35%), with complete healing in nine @entity0 (18%). @entity0 who received @entity4 were more likely to achieve a response (48%) than those without immunosuppression (15%) (P = 0.03). The @entity2 Activity Index was closely associated with treatment response and perianal disease activity. CONCLUSION: Antibiotics are useful to induce a short-term response in perianal @entity1 , and may provide a bridging strategy to @entity4 , which seems to be essential for the maintenance of fistula improvement.

title: Antibiotics and @entity4 for the treatment of perianal XXXX in @entity1 .

answer: @entity3


abstract: BACKGROUND: Antibiotics and @entity7 have been employed in the management of fistulizing @entity1 , although evidence of their efficacy is rare. AIM: To evaluate, in a prospective, open-label study, the influence of antibiotics and @entity4 on the clinical outcome of perianal @entity3 in @entity0 with @entity1 . METHODS: Fifty-two @entity0 entered the study, starting with an 8-week regimen of @entity6 (500-1000 mg/day) and/or @entity5 (1000-1500 mg/day). Seventeen @entity0 had already received daily @entity4 (2-2.5 mg/kg) at enrollment, whereas in 14 @entity0 @entity4 was initiated after 8 weeks of antibiotic treatment. Outcome was evaluated by Fistula Drainage Assessment and the @entity2 Activity Index at weeks 8 and 20. RESULTS: Overall, 26 @entity0 (50%) responded to antibiotic treatment, with complete healing in 25% of @entity0 at week 8. The @entity2 Activity Index decreased significantly from 8.4 +/- 2.9 to 6.0 +/- 4.0 (P < 0.0001). At week 20, the outcome was assessed in 49 @entity0 (94%), 29 of whom (59%) had received @entity4 . Response was noted in 17 of the 49 @entity0 (35%), with complete healing in nine @entity0 (18%). @entity0 who received @entity4 were more likely to achieve a response (48%) than those without immunosuppression (15%) (P = 0.03). The @entity2 Activity Index was closely associated with treatment response and perianal disease activity. CONCLUSION: Antibiotics are useful to induce a short-term response in perianal @entity1 , and may provide a bridging strategy to @entity4 , which seems to be essential for the maintenance of fistula improvement.

title: Antibiotics and @entity4 for the treatment of perianal @entity3 in XXXX .

answer: @entity1


abstract: BACKGROUND: Antibiotics and @entity7 have been employed in the management of fistulizing @entity1 , although evidence of their efficacy is rare. AIM: To evaluate, in a prospective, open-label study, the influence of antibiotics and @entity4 on the clinical outcome of perianal @entity3 in @entity0 with @entity1 . METHODS: Fifty-two @entity0 entered the study, starting with an 8-week regimen of @entity6 (500-1000 mg/day) and/or @entity5 (1000-1500 mg/day). Seventeen @entity0 had already received daily @entity4 (2-2.5 mg/kg) at enrollment, whereas in 14 @entity0 @entity4 was initiated after 8 weeks of antibiotic treatment. Outcome was evaluated by Fistula Drainage Assessment and the @entity2 Activity Index at weeks 8 and 20. RESULTS: Overall, 26 @entity0 (50%) responded to antibiotic treatment, with complete healing in 25% of @entity0 at week 8. The @entity2 Activity Index decreased significantly from 8.4 +/- 2.9 to 6.0 +/- 4.0 (P < 0.0001). At week 20, the outcome was assessed in 49 @entity0 (94%), 29 of whom (59%) had received @entity4 . Response was noted in 17 of the 49 @entity0 (35%), with complete healing in nine @entity0 (18%). @entity0 who received @entity4 were more likely to achieve a response (48%) than those without immunosuppression (15%) (P = 0.03). The @entity2 Activity Index was closely associated with treatment response and perianal disease activity. CONCLUSION: Antibiotics are useful to induce a short-term response in perianal @entity1 , and may provide a bridging strategy to @entity4 , which seems to be essential for the maintenance of fistula improvement.

title: Antibiotics and XXXX for the treatment of perianal @entity3 in @entity1 .

answer: @entity4


abstract: BACKGROUND: This study aimed to provide an updated analysis of @entity1 mortality rates and long-term trends to 2013 to describe the current level of @entity2 and identify changes in recent decades. METHODS: Data on number of @entity2 from @entity1 in @entity0 aged under 15  years were derived from Vital Statistics in Japan and the World Health Organization (WHO) mortality database for comparison countries. Trends in mortality were examined by fitting a joinpoint regression model. RESULTS: For all @entity1 combined, the mortality rate during 2010-2013 was 19.9 per 1,000,000 population for @entity0 and 17.5 for @entity0 in Japan. Mortality from all @entity1 combined decreased significantly from 1980 to 2003 for @entity0 and from 1980 to 2001 for @entity0 . Afterwards, the rates remained stable for both sexes. Mortality from @entity3 declined over the entire study period by 4.6  % per year (p   <0.05) in @entity0 and 4.3  % per year (p   <0.05) in @entity0 . For central nervous system (CNS) @entity1 , a slight increase in mortality was observed for both sexes, with a statistically significant annual percent change (APC) of 0.5  % (p   <0.05) for @entity0 and 0.6  % (p   <0.05) for @entity0 . CONCLUSIONS: We provided updated information on recent trends of @entity1 death. The establishment of a nationwide, @entity1 registry is required in Japan. Moreover, trends in @entity1 mortality should be monitored continuously.

title: XXXX mortality in Japan, 1980-2013.

answer: @entity1


abstract: OBJECTIVE: @entity5 of the central nervous system are rare @entity2 that can occur as @entity2 of @entity6 . With the availability of magnetic resonance imaging, asymptomatic @entity2 are detected more frequently, especially among @entity0 with @entity6 , and the questions of whether and when these lesions should be treated arise. To identify surgical outcomes and the timing of surgery for @entity5 , we retrospectively analyzed data for a series of 28 consecutive @entity0 whom we surgically treated for @entity5 in the past 10 years. METHODS: All @entity2 were completely removed. Functional grades, according to the McCormick scale, were determined before and after surgery and in follow-up assessments. Several clinical characteristics were correlated with changes in functional grades in follow-up assessments, compared with preoperative grades. RESULTS: Functional grades in follow-up assessments improved for 28.6% of the @entity0 and remained unchanged for 71.4%. No @entity0 was in worse condition, compared with preoperative status. Peritumoral @entity1 on preoperative magnetic resonance imaging scans was correlated with significantly higher surgical morbidity rates. Four asymptomatic @entity0 were surgically treated because of @entity2 or pseudocyst progression on serial magnetic resonance imaging scans. All of those @entity0 remained asymptomatic postoperatively. CONCLUSION: @entity5 can be removed with low surgical morbidity rates and excellent long-term prognoses. The timing of surgery for @entity0 with @entity6 and @entity4 remains a matter of debate. On the basis of our data, we established the strategy of operating also on asymptomatic lesions that exhibit radiological progression, before significant @entity3 occur, which are often not reversible.

title: Treatment of @entity5 , with special attention to XXXX .

answer: @entity6


abstract: OBJECTIVE: @entity5 of the central nervous system are rare @entity2 that can occur as @entity2 of @entity6 . With the availability of magnetic resonance imaging, asymptomatic @entity2 are detected more frequently, especially among @entity0 with @entity6 , and the questions of whether and when these lesions should be treated arise. To identify surgical outcomes and the timing of surgery for @entity5 , we retrospectively analyzed data for a series of 28 consecutive @entity0 whom we surgically treated for @entity5 in the past 10 years. METHODS: All @entity2 were completely removed. Functional grades, according to the McCormick scale, were determined before and after surgery and in follow-up assessments. Several clinical characteristics were correlated with changes in functional grades in follow-up assessments, compared with preoperative grades. RESULTS: Functional grades in follow-up assessments improved for 28.6% of the @entity0 and remained unchanged for 71.4%. No @entity0 was in worse condition, compared with preoperative status. Peritumoral @entity1 on preoperative magnetic resonance imaging scans was correlated with significantly higher surgical morbidity rates. Four asymptomatic @entity0 were surgically treated because of @entity2 or pseudocyst progression on serial magnetic resonance imaging scans. All of those @entity0 remained asymptomatic postoperatively. CONCLUSION: @entity5 can be removed with low surgical morbidity rates and excellent long-term prognoses. The timing of surgery for @entity0 with @entity6 and @entity4 remains a matter of debate. On the basis of our data, we established the strategy of operating also on asymptomatic lesions that exhibit radiological progression, before significant @entity3 occur, which are often not reversible.

title: Treatment of XXXX , with special attention to @entity6 .

answer: @entity5


abstract: The clinical features of @entity2 media (TOM) have changed. This study was performed to evaluate changing trends in the clinical manifestations of TOM. We reviewed a series of 12 cases of TOM (13 ears) recently treated at Osaka Prefectural Habikino Hospital. The results showed a mean age of 41 years and a male predominance of 1.4 to 1. Central or total perforations of the tympanic membrane were observed in most cases, but none of the @entity0 had multiple perforations. Nine @entity0 (75%) had @entity3 . Normal lung status or @entity3 was significantly more frequent in the older age group. Diagnosis of primary TOM required more time than that of secondary TOM. Most cases of primary TOM had high infectiousness of the @entity1 . We summarize the clinical features of @entity0 who should be evaluated for TOM.

title: XXXX media: clinical aspects of 12 cases.

answer: @entity2


abstract: @entity5 has single-drug activity in @entity4 ( @entity4 ), and may enhance the formation of the active metabolite ( @entity7 ) of @entity3 ( @entity3 ). To evaluate the feasibility of adding intermittent @entity5 to intermediate-dose ara-C (1 g/m2/2 h) b.i.d. for 4 d with @entity6 (CCI), we performed a 2:1 randomized phase II trial in @entity4 @entity0 aged over 60 years. Primary endpoints were time to recovery from cytopenia and need for supportive care following the first course. Sixty-three @entity0 (median 71 years, range 60-84 years) were included, constituting 72% of all eligible @entity0 . @entity1 was limited, with no differences between the treatment arms. The early toxic death rate was 11%. The median time to recovery from neutropenia and @entity2 was 22 and 17 d from the start of course no. 1, respectively, and the requirement for platelet and red cell transfusions was four and eight units respectively. @entity0 had a median of 8 d with fever over 38 degrees C, and 17 d with intravenous antibiotic treatment. The overall complete remission (CR) rate was 62%, with 51% CR from one course of CCI in comparison with 35% for the two-drug therapy (P = 0.014). The median survival with a 2-year follow-up was 14 months, and the 2-year survival was over 30%, with no differences between the treatment arms. Considering the median age and our population-based approach, the overall results are encouraging.

title: Increased remissions from one course for intermediate-dose @entity3 and XXXX in elderly @entity4 when combined with @entity5 . A randomized population-based phase II study.

answer: @entity6


abstract: @entity5 has single-drug activity in @entity4 ( @entity4 ), and may enhance the formation of the active metabolite ( @entity7 ) of @entity3 ( @entity3 ). To evaluate the feasibility of adding intermittent @entity5 to intermediate-dose ara-C (1 g/m2/2 h) b.i.d. for 4 d with @entity6 (CCI), we performed a 2:1 randomized phase II trial in @entity4 @entity0 aged over 60 years. Primary endpoints were time to recovery from cytopenia and need for supportive care following the first course. Sixty-three @entity0 (median 71 years, range 60-84 years) were included, constituting 72% of all eligible @entity0 . @entity1 was limited, with no differences between the treatment arms. The early toxic death rate was 11%. The median time to recovery from neutropenia and @entity2 was 22 and 17 d from the start of course no. 1, respectively, and the requirement for platelet and red cell transfusions was four and eight units respectively. @entity0 had a median of 8 d with fever over 38 degrees C, and 17 d with intravenous antibiotic treatment. The overall complete remission (CR) rate was 62%, with 51% CR from one course of CCI in comparison with 35% for the two-drug therapy (P = 0.014). The median survival with a 2-year follow-up was 14 months, and the 2-year survival was over 30%, with no differences between the treatment arms. Considering the median age and our population-based approach, the overall results are encouraging.

title: Increased remissions from one course for intermediate-dose @entity3 and @entity6 in elderly @entity4 when combined with XXXX . A randomized population-based phase II study.

answer: @entity5


abstract: @entity5 has single-drug activity in @entity4 ( @entity4 ), and may enhance the formation of the active metabolite ( @entity7 ) of @entity3 ( @entity3 ). To evaluate the feasibility of adding intermittent @entity5 to intermediate-dose ara-C (1 g/m2/2 h) b.i.d. for 4 d with @entity6 (CCI), we performed a 2:1 randomized phase II trial in @entity4 @entity0 aged over 60 years. Primary endpoints were time to recovery from cytopenia and need for supportive care following the first course. Sixty-three @entity0 (median 71 years, range 60-84 years) were included, constituting 72% of all eligible @entity0 . @entity1 was limited, with no differences between the treatment arms. The early toxic death rate was 11%. The median time to recovery from neutropenia and @entity2 was 22 and 17 d from the start of course no. 1, respectively, and the requirement for platelet and red cell transfusions was four and eight units respectively. @entity0 had a median of 8 d with fever over 38 degrees C, and 17 d with intravenous antibiotic treatment. The overall complete remission (CR) rate was 62%, with 51% CR from one course of CCI in comparison with 35% for the two-drug therapy (P = 0.014). The median survival with a 2-year follow-up was 14 months, and the 2-year survival was over 30%, with no differences between the treatment arms. Considering the median age and our population-based approach, the overall results are encouraging.

title: Increased remissions from one course for intermediate-dose XXXX and @entity6 in elderly @entity4 when combined with @entity5 . A randomized population-based phase II study.

answer: @entity3


abstract: @entity5 has single-drug activity in @entity4 ( @entity4 ), and may enhance the formation of the active metabolite ( @entity7 ) of @entity3 ( @entity3 ). To evaluate the feasibility of adding intermittent @entity5 to intermediate-dose ara-C (1 g/m2/2 h) b.i.d. for 4 d with @entity6 (CCI), we performed a 2:1 randomized phase II trial in @entity4 @entity0 aged over 60 years. Primary endpoints were time to recovery from cytopenia and need for supportive care following the first course. Sixty-three @entity0 (median 71 years, range 60-84 years) were included, constituting 72% of all eligible @entity0 . @entity1 was limited, with no differences between the treatment arms. The early toxic death rate was 11%. The median time to recovery from neutropenia and @entity2 was 22 and 17 d from the start of course no. 1, respectively, and the requirement for platelet and red cell transfusions was four and eight units respectively. @entity0 had a median of 8 d with fever over 38 degrees C, and 17 d with intravenous antibiotic treatment. The overall complete remission (CR) rate was 62%, with 51% CR from one course of CCI in comparison with 35% for the two-drug therapy (P = 0.014). The median survival with a 2-year follow-up was 14 months, and the 2-year survival was over 30%, with no differences between the treatment arms. Considering the median age and our population-based approach, the overall results are encouraging.

title: Increased remissions from one course for intermediate-dose @entity3 and @entity6 in elderly XXXX when combined with @entity5 . A randomized population-based phase II study.

answer: @entity4


abstract: UNASSIGNED: A novel method of harvesting whole-plant @entity1 silage, shredlage, may increase kernel processing and physically effective fiber. Improved fiber effectiveness may be especially advantageous when feeding brown midrib (BMR) @entity1 hybrids, which have reduced lignin content. The objective of this study was to determine the effect of feeding TMR containing BMR @entity1 shredlage (SHRD) compared with BMR conventionally processed @entity1 silage (KP) or KP plus chopped alfalfa hay (KPH) on intake, lactation performance, and total-tract nutrient digestibility in dairy @entity0 . The KP was harvested using conventional rolls (2-mm gap) and the self-propelled forage harvester set at 19 mm of theoretical length of cut, whereas SHRD was harvested using novel cross-grooved rolls (2-mm gap) and the self-propelled forage harvester set at 26 mm of theoretical length of cut. Holstein @entity0 (n = 120; 81    8 d in @entity2 at trial initiation), stratified by parity, days in @entity2 , and @entity2 yield, were randomly assigned to 15 pens of 8 @entity0 each. Pens were randomly assigned to 1 of 3 treatment diets, SHRD, KP, or KPH, in a completely randomized design using a 2-wk covariate period with @entity0 fed a common diet followed by a 14-wk treatment period with @entity0 fed their assigned treatment diet. The TMR contained (dry matter basis) KP or SHRD forages (45%), alfalfa silage (10%), and a concentrate mixture (45%). Hay replaced 10% of KP silage in the KPH treatment TMR (dry matter basis). @entity2 , protein, and lactose yields were 3.4, 0.08, and 0.16 kg/d greater, respectively, for @entity0 fed KP and SHRD than KPH. A week by treatment interaction was detected for @entity2 yield, such that @entity0 fed SHRD produced or tended to produce 1.5 kg/d per @entity0 more @entity2 , on average, than @entity0 fed KP during 6 of the 14 treatment weeks. Component-corrected @entity2 yields were similar among treatments. @entity0 fed KPH had greater @entity2 fat concentration than @entity0 fed KP and SHRD (3.67 vs. 3.30% on average). Consumption of dry matter, rumination activity, and sorting behavior were similar among treatments. Ruminal in situ starch digestibility was greater for SHRD than KP forages, and total-tract dietary starch digestibility was greater for SHRD than KP. @entity2 yield and starch digestibility were greater for SHRD than KP. Lack of improvement in @entity2 fat content and rumination activity for SHRD compared with KP and reduced @entity2 fat content for SHRD compared with KPH, however, suggest no improvement in physically effective fiber from the longer theoretical length of cut used with SHRD in a BMR hybrid.

title: Brown midrib @entity1 shredlage in diets for high-producing dairy XXXX .

answer: @entity0